Piper Sandler Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $61
Piper Sandler analyst Edward Tenthoff initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $61.
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
RAPT Therapeutics Raises $125M Via Equity At 6% Discount
RAPT Therapeutics Inc (NASDAQ:RAPT) has priced its previously announced underwritten public offering of 3.8 million shares at $33/share. The price represents…
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
60 Biggest Movers From Yesterday
Gainers
RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.74% to 34,225.89 while the NASDAQ rose 0.45% to 14,132.55. The S&P also fell, dropping 0.27% to 4,236.03.